Retsina Meyer, PhD, Head of strategic projects and Alliances at Delix Therapeutics. Boad of Advisors, Museum of Science, Boston, MA. She leverages her background in neuroscience, endocrinology, and business strategy to advance the field of personalized medicine in neurological disorders. Notably, Dr. Meyer founded Resilience Therapeutics, a drug development company advancing disease-modifying therapeutics for PTSD. With a successful strategic sale, Resilience advanced a novel therapeutic with measurable biomarkers into the clinic. Dr. Meyer recently served as Project Lead for a national initiative to roadmap the path forward for precision medicine in trauma-related brain disorders. The ensuing deliverables will serve the field to guide research, development, and funding for diagnostics and therapeutics. Retsina served as a Fulbright Scholar at the Norwegian Institute of Technology Center for the Biology of Memory with the Moser Lab (2014 Nobel Prize Winners); earned a PhD in Systems Neuroscience and Neuroendocrinology from MIT; and Bachelor’s Degrees in Applied Mathematics, Biochemistry and Molecular Biophysics, and Biological Psychology from the University of Arizona Honors College.